Evidence map›Paper›PMID 38994539›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2021

Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study.

Staffan Jahnson, Truls Gårdmark, Abolfazl Hosseini, Tomas Jerlström, Fredrik Liedberg, Per-Uno Malmström, Oskar Hagberg, Amir Sherif, Viveka Ströck, Karin Söderkvist and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Staffan JahnsonDepartment of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
Truls GårdmarkDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Abolfazl HosseiniDepartment of Pelvic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Tomas JerlströmDepartment of Urology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Fredrik LiedbergDepartment of Urology, Skåne University Hospital, Malmö, Sweden and Institution of Translational Medicine, Lund University, Malmö, Sweden.
Per-Uno MalmströmDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Oskar HagbergInstitution of Translational Medicine, Lund University, Malmö, Sweden.
Amir SherifDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Viveka StröckDepartment of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden and Region Västra Götaland, Sahlgrenska University Hospital, Department of Urology, Gothenburg, Sweden.
Karin SöderkvistDepartment of Radiation Sciences - Oncology, Umeå University, SE-90185 Umeå, Sweden.
Anders UllenDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden and Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Solna, Sweden.
Christel HäggströmDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Lars HolmbergDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Firas AljaberyDepartment of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRoutine VTE prophylaxis within 30 days of radical cystectomy (RC) for urinary bladder cancer (UBC) is used to protect from venous thromboembolism (VTE). However, randomized studies and nationwide population-based studies are lacking.

objectiveTo study VTE and risk factors for VTE in muscle-invasive UBC in a nationwide population-based series, with a focus on the association with RC with and without chemotherapy. MATERIALS AND

methodsWe studied all patients with clinical stage T2-T4 UBC diagnosed 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe). Previous VTE events and risk factors for VTE were registered from 1987. Cox regression analyses and Kaplan-Meier curves were performed to study risk factors for VTE and cumulative incidence of VTE.

resultsIn 9720 patients (71%males) with a median age of 74 years 546 (5.6%) had VTE after diagnosis. In Cox analyses controlling for patient's and tumour characteristics, and risk factors for VTE, VTE after diagnosis and first treatment date were associated with chemotherapy with or without RC. Cumulative incidence of VTE increased during 24 months after diagnosis and first treatment date. VTE were less common in patients with previous cardiovascular disease.

conclusionsVTE was commonly observed after 30 days from diagnosis and from first treatment date in patients with T2-T4 UBC, particularly after chemotherapy. The findings suggest that long-term intervention studies of benefit and possible harms of VTE prophylaxis after UBC should be undertaken.

Indexed as

Bladder cancerchemotherapycystectomypopulation-basedprophylaxisvenous thromboembolism

Identifiers

PMID38994539
PMCPMC11181779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.